Engflag

Proglicem 25

Quick links to important sections

Proglicem 25

Proglicem 25_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proglicem 25

Property Description
Active ingredient Diazoxide
Form Capsule (25 mg) and Oral Suspension (Liquid)
Pharmacological class Glucose-Elevating Agent (Antihypoglycemic)
Common use Management of persistent low blood sugar due to excess insulin
Origin Synthetic

What Type of Medicine is Proglicem 25?

Proglicem 25 is a specialized synthetic prescription medication. Its active ingredient is Diazoxide, which is clinically classified as a Glucose-Elevating Agent. This classification distinguishes it as a medication designed to raise blood sugar levels, contrasting with drugs that typically lower glucose.

A significant feature of this medicine is its targeted use against hyperinsulinemic hypoglycemia—low blood sugar caused by the body producing excessive amounts of insulin. Diazoxide is indicated primarily for hypoglycemia due to hyperinsulinism.

What Forms and Composition Does Proglicem Come In?

Proglicem is a recognized brand that is available for oral use in two primary forms: a 25 mg capsule and an oral suspension (liquid). The liquid form is a key feature, often making the medication suitable for infants and young children who may be unable to swallow capsules, which is a common need for this specific condition.

The high-level composition relies entirely on the therapeutic action of the active component, Diazoxide, combined with necessary inactive ingredients (excipients). The primary function is derived from the properties of the active ingredient itself.

What is the General Purpose of Proglicem?

The general purpose of Proglicem is to provide consistent, long-term stabilization of blood sugar in patients diagnosed with hyperinsulinism. This corrective action helps maintain glucose levels above dangerous thresholds. A typical use scenario involves a patient requiring daily medication to prevent recurrent episodes of severe hypoglycemia, thereby managing symptoms and supporting overall health stability.

Regulatory References

  1. Diazoxide Oral Suspension Label - DailyMed (NLM)

What side effects are possible with Proglicem 25?

Possible Side Effects and Safety Information

Proglicem (Diazoxide) has an officially documented safety profile characterized by effects on metabolism, fluid balance, and cardiovascular function. This profile is defined by frequency classifications and System-Organ-Classes (SOC) as listed in regulatory documents.

Key Regulatory Safety Classifications

Classification Tier Primary Documented Effects
Most Common Reactions Hyperglycemia, Edema (fluid retention/swelling), and Hypertrichosis (excessive hair growth).
Serious Adverse Reactions Precipitation of Congestive Heart Failure, Diabetic Ketoacidosis, Hyperosmolar Nonketotic Coma (HHS), and Pulmonary Hypertension (noted in neonates/infants).

System-Organ Classes and Population-Specific Notes

Adverse reactions are reported across several systems, including Metabolic and Nutritional Disorders, Cardiac Disorders, Vascular Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders. Gastrointestinal complaints such as nausea, vomiting, and abdominal discomfort are listed as frequent reactions.

Safety notes explicitly address specific populations: Newborns and Infants have an increased risk for severe adverse effects, including Necrotizing Enterocolitis (reported post-marketing) and Pulmonary Hypertension. Use in late pregnancy may lead to fetal/neonatal effects such as altered carbohydrate metabolism and thrombocytopenia in the infant. The medicine is formally contraindicated in individuals with Functional Hypoglycemia.

Hyperglycemic and hyperuricemic actions of the drug may be potentiated if used with thiazide diuretics. The Hypertrichosis associated with long-term exposure is described in official documents as subsiding upon discontinuation of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Manifestations and Immediate Action

Overdosage with Proglicem (Diazoxide) is officially documented in prescribing information to cause marked hyperglycemia, which represents a severe elevation of blood sugar. Because of this profound increase in glucose, the official labeling warns that the overdose can be associated with serious metabolic outcomes, including the development of ketoacidosis and the life-threatening condition of nonketotic hyperosmolar coma. Immediate medical attention is required when an overdose is suspected or confirmed. The documented emergency response requires specific therapeutic actions, including prompt insulin administration to manage the high blood sugar and the restoration of fluid and electrolyte balance to stabilize the patient's condition.

Monitoring and Special Considerations

The management of a Proglicem overdose requires extended care and observation. Due to the drug's prolonged half-life, which is approximately 30 hours, regulatory sources mandate a period of prolonged surveillance. This mandatory hospital monitoring may last for up to seven days and must continue until the blood sugar level is confirmed to have stabilized within the normal range. Furthermore, official labeling notes that individuals with impaired renal function may experience a further extension of the drug's half-life. This factor may necessitate an adjustment to the required duration of post-acute surveillance. No specific chemical antidote is listed in the official regulatory documentation.

Therapeutic Uses of Proglicem 25

What Proglicem 25 Treats: Main Uses and Benefits

Proglicem (Diazoxide) is applied across a defined set of conditions related to excess insulin production. The medicine is commonly used to help manage symptoms related to systemic imbalance by supporting blood sugar levels. Generally, the medication is indicated for the management of hypoglycemia due to hyperinsulinism.

Management of Chronic Hyperinsulinemic Hypoglycemia

This medication is commonly used across conditions presenting with chronic hyperinsulinemic hypoglycemia, applicable to conditions such as congenital hyperinsulinism in children and hypoglycemia caused by inoperable pancreatic tumors in adults. It is applied across domains where additional symptomatic support is needed to address low blood sugar. This application may assist with maintaining functional stability in situations where patients experience symptomatic imbalance.

Proglicem is also relevant for managing symptoms that create noticeable physiological strain, especially the risk of seizures and potential neurological effects from glucose deprivation. In situations where patients experience systemic imbalance, the treatment supports the patient during difficult episodes and contributes to improved comfort during periods of heightened symptoms, which is important for the developing brains of infants and children.

Quick Fact: Relief for Hypoglycemia
Proglicem is commonly used to help manage symptoms related to recurrent, severe low blood sugar caused by excess insulin.

Regulatory References

  1. Label: PROGLYCEM- diazoxide suspension - DailyMed - NIH

Eligibility and Restrictions for Use

Proglicem (Diazoxide) is an established treatment for managing hypoglycemia due to hyperinsulinism in adults, children, and infants with specific diagnosed conditions. The official prescribing information establishes the following rules for eligibility:

Eligibility Scope

Population Status Classification
Use is Contraindicated Functional Hypoglycemia (low blood sugar not caused by excess insulin) or known hypersensitivity to diazoxide or related thiazide medicines.
Use is Established Adults, Infants, and Children with hypoglycemia due to specific conditions like congenital hyperinsulinism or inoperable islet cell tumors.

Condition-Based Restrictions

Newborns and Infants require careful monitoring due to the post-marketing risk of Pulmonary Hypertension. Use in patients with impaired renal function requires caution because the drug’s half-life is prolonged, affecting how it is cleared from the body. Compromised cardiac reserve is a condition that also requires caution due to the risk of fluid retention, which may worsen heart failure.

Physiological and Age Limitations

The drug is classified as Pregnancy Category C; use is conditional and only permitted if the potential benefit to the mother outweighs the possible risk to the fetus. For nursing mothers, a decision must be made to discontinue the drug or discontinue nursing. Geriatric patients have no specific data available to determine effects in that age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Proglicem (Diazoxide) is defined by pharmacokinetic changes and pharmacodynamic synergism, according to regulatory documents.

Classification Interacting Substance/Class Official Interaction Statement
Contraindicated Other Thiazides Prohibited due to the established risk of cross-hypersensitivity reactions.
Pharmacodynamic Benzothiazide Diuretics Co-administration may intensify the hyperglycemic and hyperuricemic effects of Diazoxide.
Pharmacokinetic Coumarin Derivatives (e.g., Warfarin) Diazoxide is highly protein bound and may displace these anticoagulants, resulting in higher plasma levels.
Pharmacokinetic Diphenylhydantoin (Phenytoin) Concomitant use may result in a loss of seizure control due to altered metabolism of Phenytoin.

Population and Context Constraints

Proglicem's pharmacokinetic profile is significantly altered in certain clinical contexts. In patients with impaired renal function, the plasma half-life of Diazoxide is prolonged, which must be considered due to altered drug exposure. Additionally, official documents caution that due to its strong protein binding, Proglicem may displace bilirubin from albumin, an interaction of particular concern when treating newborns. The antihypertensive effect of other medicines may also be enhanced when co-administered with this medication.

The overall interaction structure establishes constraints for co-administration, noting specific combinations that lead to altered drug exposure or enhanced pharmacologic effects, such as intensified hyperglycemia or increased levels of highly protein-bound medicines.

Mechanism of Action

Proglicem 25, containing Diazoxide, works through a precise pharmacological action focused on modulating the electrical activity of specific ion channels. This mechanism is designed to suppress excessive hormone release and modulate systemic activity.

Ion Channel Activation and Membrane Hyperpolarization

The drug's primary action is the activation and opening of the ATP-sensitive potassium channel ( KATP channel) located on pancreatic beta-cells, achieved by binding to the SUR1 subunit. This interaction causes a rapid outward flow of potassium ions ( K^+), fundamentally altering the cell's electrical potential and inducing hyperpolarization. This step initiates the core molecular mechanism for systemic regulation.

Disruption of the Insulin Secretion Cascade

The resulting cellular hyperpolarization directly inhibits the activation of voltage-gated calcium channels, thereby preventing the calcium influx ( Ca^2+) that triggers insulin granule exocytosis. This disruption is a targeted interference in the hormonal cascade, leading to a profound inhibition of insulin secretion and consequently resulting in a physiological reduction of the glucose-lowering drive.

️ Secondary Physiological Effects

While primarily focused on the pancreas, the drug's mechanism of KATP channel activation extends to non-pancreatic tissues, including arteriolar smooth muscle. This action causes vasodilation and also influences channels regulating fluid transport in the kidney, contributing to secondary physiological effects, including a tendency toward sodium and water retention.

Dosage and Administration Information

Proglicem (Diazoxide) is an oral medication available as a capsule and a concentrated oral suspension (50 mg/mL). The total daily amount is determined by body weight and is split into two or three equal doses. This divided dosing pattern is essential for maintaining consistent levels of the drug in the body over a 24-hour period.

Dosing and Schedule Principles

The administration of Proglicem is calculated on a per-kilogram basis. For adults and older children, the typical daily dose ranges from 3 to 8 mg/kg. Infants and newborns generally require a higher dose range of 8 to 15 mg/kg per day. The total daily amount must be divided and taken on a regular schedule every 8 or 12 hours.

Administration Guidance

For the liquid suspension, the bottle must be shaken well before each use. To ensure the accuracy necessary for weight-based dosing, the suspension must be measured using an accurate, calibrated device provided with the medication. If a dose is missed, it should be taken as soon as remembered, but the user should skip the dose entirely if it is almost time for the next scheduled dose; doses should never be doubled.

Treatment Protocol

Treatment initiation requires close supervision by a healthcare professional for several days until the patient's glucose levels have stabilized. The medication is subject to a mandatory trial period; if the medication is not effective after two to three weeks, discontinuation is indicated. Furthermore, a reduced dosage should be considered for patients with impaired kidney function due to the potential for prolonged drug presence in the body.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Proglicem 25

Proglicem 25 (Diazoxide) was studied in research exploring the condition of chronic low blood sugar (hypoglycemia) caused by excess insulin (hyperinsulinism). Because hyperinsulinism is a rare condition, the body of research relies primarily on observational cohort studies, patient registries, and systematic reviews, rather than large randomized, placebo-controlled trials. These studies examine patterns related to patient experience and clinical changes.

Evidence for Use in Hyperinsulinemic Hypoglycemia

The main focus of these studies was to examine the patient’s clinical response to therapy. Researchers examined the patterns of blood glucose values measured in observed populations, and the proportion of patients who showed a successful clinical response. These findings describe patterns observed in the studies regarding blood glucose levels over defined time intervals.

The existing research base was evaluated in a range of patient populations. The majority of the published evidence has explored its use in Infants and Children with Congenital Hyperinsulinism (CHI), as well as Adults whose hyperinsulinism is secondary to an inoperable tumor. Studies also examine patients defined by specific genetic characteristics (e.g., K-ATP channel status) to see how these factors may influence the clinical response.

What is Still Uncertain About Proglicem 25 Research

While the research base contributes to the broader evidence landscape, several areas of uncertainty and limitation remain insufficient. Long-term effects are not fully established, and follow-up durations were limited in many key studies.

Furthermore, patient heterogeneity is a major research limitation; the findings were mixed across patient groups. Studies reported measurements of a non-response rate that was observed in some patient groups, particularly among patients with certain genetic defects. Comparative evidence is lacking, as studies often do not compare the drug against other treatments, and certainty remains low when evaluating the drug's relative impact.

Key Studies & References

  1. PROGLYCEM- diazoxide suspension: U.S. National Library of Medicine Drug Label

Frequently Asked Questions (FAQ)

Common questions about Proglicem 25 (FAQ)

Q: What happens if I miss a dose of Proglicem 25?

If a dose is missed, official administration guidance suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose completely. Regulatory guidance states that doses must not be doubled.

Q: Can people with kidney problems use Proglicem 25?

Official documentation advises caution for use in patients with impaired renal function (kidney problems). Regulatory documents note that the medicine may stay in the body for a longer time in this population, which is why a reduced dosage may be considered.

Q: What if Proglicem 25 doesn't seem to be helping my condition?

Treatment with Proglicem is subject to a mandatory trial period. According to official protocol, if the medication is determined to be ineffective after a period of two to three weeks, official protocol indicates that the treatment should be discontinued.

Q: How can I tell if Proglicem 25 is actually working for me?

Official documents note that treatment initiation requires close supervision until a patient's blood glucose levels have stabilized. Research evidence also focuses on examining the patterns of blood glucose values and the proportion of patients who achieve stability.

Q: How is Proglicem 25 different from similar sounding medicines?

Proglicem is classified as a Glucose-Elevating Agent, meaning its purpose is to raise blood sugar by inhibiting insulin release. This provides a clear distinction from other glucose-modifying agents that are designed to lower glucose levels.

Q: Does Proglicem 25 interact with supplements like vitamins or herbal remedies?

While regulatory documents list interactions with specific prescription medicines, there is no explicit information provided in official sources regarding interactions with vitamins or herbal supplements.

Q: Is Proglicem 25 the same type of medicine as other blood sugar treatments?

Proglicem is classified as a Glucose-Elevating Agent, and its core function is to raise blood sugar by reducing the amount of insulin the body produces. This action makes it distinct from treatments designed to lower blood sugar in conditions like Type 2 Diabetes.

Q: Does Proglicem 25 cause weight changes or appetite changes?

Official safety documents list anorexia, or a loss of appetite, as a reported adverse reaction. Additionally, edema (fluid retention or swelling) is frequently reported in patients, which is a factor that may affect weight measurements.

Q: Can Proglicem 25 affect my sleep or energy levels?

Official safety information lists insomnia (difficulty sleeping) as a reported adverse reaction. Additionally, some patients have reported experiencing asthenia (weakness or lack of energy) and a general feeling of malaise.

Q: What is the difference between Proglicem 25 and metformin, if any?

Proglicem is a Glucose-Elevating Agent prescribed to raise blood sugar by inhibiting insulin release. Metformin is generally used to lower blood sugar. Regulatory information notes that Proglicem may decrease the effects of Metformin via pharmacodynamic antagonism.

Q: Can Proglicem 25 be taken long-term?

Proglicem is indicated for the long-term management of persistent low blood sugar due to excess insulin (hyperinsulinism). Although a trial period is mandatory at the start of treatment, official documents do not set a specific time limit for use in patients who respond well.

Q: Is Proglicem 25 habit-forming or addictive?

Proglicem (Diazoxide) is not classified as a controlled substance by regulatory bodies in the US or Canada. This classification indicates that the medicine does not carry a risk of dependence or addiction.

Q: Why is Proglicem 25 sometimes used for conditions other than diabetes?

Proglicem is specifically indicated for low blood sugar (hypoglycemia) caused by the body producing too much insulin (hyperinsulinism). This condition is often related to specific genetic conditions or tumors, and its use is specialized for specific diagnosed conditions, not the treatment of Type 1 or Type 2 Diabetes.

Q: Are there any warnings about using Proglicem 25 with alcohol?

There are no specific drug-alcohol interactions listed in regulatory documents for the capsule form. However, it is noted that the liquid oral suspension formulation contains approximately 7.25% alcohol (ethanol), which must be considered.

Q: Does Proglicem 25 affect blood pressure or heart rate?

Yes, official safety documents indicate that Proglicem is associated with changes in cardiovascular function. Reported adverse reactions include hypotension (low blood pressure), tachycardia (fast heart rate), and palpitations (a sensation of a fast or pounding heart).

Q: Is it normal to feel tired or dizzy after starting Proglicem 25?

Dizziness is listed as a reported adverse reaction in the official safety profile. Other general complaints, such as malaise (general discomfort) and asthenia (weakness or lack of energy), are also reported.

Q: What lifestyle changes are typically recommended alongside using Proglicem 25?

Official patient information advises users to strictly follow the specific dietary instructions provided by their healthcare provider. Maintaining a regular and precise dosing schedule is also emphasized as a critical part of the treatment protocol.

Q: What is the clinical evidence theme supporting the use of Proglicem 25?

The research evidence supporting the medicine is focused on observational studies that examine patient response. The primary theme is describing patterns of blood glucose values and the proportion of patients who achieve stable blood sugar control with the medicine.

Q: Does Proglicem 25 have a risk of causing low blood sugar?

Proglicem is indicated to manage persistent low blood sugar, and its mechanism is designed to reduce insulin release and raise glucose levels. The drug is classified as a Glucose-Elevating Agent.

Q: Can Proglicem 25 be crushed or cut?

Proglicem is provided as both a capsule and a liquid oral suspension. The liquid form is available to allow for accurate weight-based dosing for patients who cannot swallow capsules. Regulatory documents do not provide instructions for cutting or crushing the capsule form.

Q: How does Proglicem 25 relate to other 'gliptin' or 'flozin' medicines?

Proglicem is a different type of medicine that raises blood sugar by activating a specific ion channel to inhibit insulin release. 'Gliptins' and 'flozins' are separate classes of drugs generally used to lower blood sugar in Type 2 Diabetes through different mechanisms.

Q: Can I stop using Proglicem 25 suddenly without any issues?

Proglicem is prescribed for a chronic medical condition (low blood sugar due to hyperinsulinism). As Proglicem is indicated for chronic low blood sugar, abrupt discontinuation may result in a recurrence of the original condition.

Q: Is Proglicem 25 safe for people with liver problems?

Regulatory documents do not contain explicit contraindications for pre-existing liver problems. However, the safety profile reports some adverse hepatic reactions, such as increases in specific liver enzymes. The appearance of these effects may be a factor requiring closer supervision.

Q: What is the risk of a potential allergic reaction to Proglicem 25?

Proglicem is contraindicated, meaning it should not be used, if a patient has a known hypersensitivity to the active ingredient, Diazoxide, or related thiazide medicines. Symptoms of a severe allergic reaction may include breathing difficulty, swelling of the face, or severe rash.

Q: Has Proglicem 25 been studied in children or adolescents?

Yes, regulatory documents confirm that the safety and efficacy of Proglicem have been established in pediatric patients, ranging from birth up to 18 years of age. It is specifically indicated for use in infants and children with certain hyperinsulinism conditions.

How should Proglicem 25 be stored and disposed of?

How to Store and Dispose of Proglicem 25?

The storage and disposal of Proglicem (diazoxide) 25 mg capsules must follow specific regulatory requirements to maintain product stability and ensure safety.

Proglicem must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and kept in a tightly closed container.

  • Protection: The medicine requires protection from light and moisture.
  • Child Safety: It must always be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Proglicem must not be flushed down the toilet or poured into a drain. For proper disposal of the medication, patients should consult a pharmacist or local waste disposal company to ensure safe handling and prevention of environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Proglicem 25 found in:

A-Z Index: